Highlights
- •Non-statin lipid-lowering therapies reduce residual ASCVD risk.
- •Utilization of non-statin therapies is low for secondary prevention.
- •There has been limited uptake of non-statin therapies in the last several years.
- •Increasing use of these therapies is paramount to improving the treatment gap.
Abstract
Keywords
Abbreviations:
ASCVD (atherosclerotic cardiovascular disease), PCSK9i (proprotein convertase subtilisin/kexin type 9 inhibitors), EHR (electronic health record), LLT (lipid-lowering therapies)Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Clinical LipidologyReferences
- Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis.J. Clin. Lipidol. 2017; 11: 1223-1233
- Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US.JAMA Cardiol. 2021; 6: 1060-1068
- Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.N. Engl. J. Med. 2018; 380: 11-22
- Ezetimibe added to statin therapy after acute coronary syndromes.N. Engl. J. Med. 2015; 372: 2387-2397
- Evolocumab and clinical outcomes in patients with cardiovascular disease.N. Engl. J. Med. 2017; 376: 1713-1722
- Alirocumab and cardiovascular outcomes after acute coronary syndrome.N. Engl. J. Med. 2018; 379: 2097-2107
- AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J. Am. Coll. Cardiol. 2018; 73 (2019): 3168-3209
- Eligibility, clinical outcomes, and budget impact of pcsk9 inhibitor adoption: the CANHEART PCSK9 study.J. Am. Heart Assoc. 2018; 7e010007
- Eligibility and cost for icosapent ethyl based on the REDUCE-IT Trial.Circulation. 2019; 139: 1341-1343
- Adoption of PCSK9 inhibitors among patients with atherosclerotic disease.J. Am. Heart Assoc. 2021; 10e019331
- Safety and efficacy of bempedoic acid to reduce LDL Cholesterol.N. Engl. J. Med. 2019; 380: 1022-1032
- Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.N. Engl. J. Med. 2020; 382: 1507-1519
- Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance.J. Am. Heart Assoc. 2019; 8e011662
Article info
Publication history
Publication stage
In Press Journal Pre-ProofFootnotes
Disclosure: AM Navar has received funding for research to her institution from BMS, Esperion, and Janssen, and honoraria and consulting fees from Astra Zeneca, BI, Bayer, Janssen, Lilly, Novo Nordisk, Novartis, New Amsterdam, Cerner, and Pfizer. NP Shah has received research funding from Amgen, Janssen, and Novartis, and honoraria and consulting fees from Amgen, Novartis, and Esperion. ED Peterson has received research funding to his institution from BMS, Esperion, Janssen, and Amgen, and honoraria and consulting fees from Bayer, Novo Nordisk, Cerner Enviza, and Novartis. CK Bradley, AA Kolkailah, and C Page have nothing to disclose.
Authors contributions: AMN and CBP had full access to the data in the study and take responsibility for the accuracy of the data analysis. CKB, AAK, NPS, EDP, and AMN were responsible for study concept and design. AMN and CBP were responsible for data analysis. CKB was responsible for drafting the article. CKB, AAK, NPS, EDP, and AMN were responsible for critically revising the article. All listed authors have approved the final manuscript.
Funding: This project was supported by grant funding to Duke University and UT Southwestern Medical Center from Janssen. The sponsor had no role in the development of the analytic plan, data analysis, data interpretation, or decision to publish.
